FIG 1.

Schematic representation of protein selection and validation. Protein antigens were selected based on conservation, physiochemical properties (e.g., subcellular localization, transmembrane domains), and predicted number and affinity of MHC epitopes. In silico predictions were then validated by confirming seroreactivity with convalescent human and experimental murine melioidosis sera. Proteins were then incorporated into a nanoglycoconjugate vaccine and evaluated for immunogenicity in mice.